GlassScriptPhysician profile
Caresse L Wesley
NPI 1841462322
$1,785.94
in general payments reported to CMS, 2019-2025
20 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.02 · 2020: $15.94 · 2021: $49.22 · 2022: $106 · 2023: $281 · 2024: $729 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.37 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $331.17 | 2021-2025 | Ubrelvy |
| Pfizer INC. | $163.43 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $111.82 | 2024-2025 | Unithroid |
| Exact Sciences Corporation | $110.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.01 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $73.88 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Azurity Pharmaceuticals, INC. | $71.20 | 2023-2025 | Azmiro, Horizant, Adthyza |
| Axsome Therapeutics, INC. | $63.58 | 2025 | Symbravo |
| Astellas Pharma US INC | $55.75 | 2023-2024 | Myrbetriq, Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $34.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $30.23 | 2024-2025 | Airsupra |
| Hologic Sales and Service, LLC | $23.25 | 2025 | Thinprep 2000 Processor, Aptima |
| Phadia US INC. | $22.44 | 2023 | Immunocap |
| Sobi, INC | $21.81 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21.20 | 2021 | |
| Cipher Pharmaceuticals US LLC | $20.62 | 2025 | Spinosad, Natroba |
| Ironwood Pharmaceuticals, INC | $16.96 | 2024 | |
| Merck Sharp & Dohme LLC | $15.94 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caresse Wesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.